Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2297714rdf:typepubmed:Citationlld:pubmed
pubmed-article:2297714lifeskim:mentionsumls-concept:C0024299lld:lifeskim
pubmed-article:2297714lifeskim:mentionsumls-concept:C0444956lld:lifeskim
pubmed-article:2297714lifeskim:mentionsumls-concept:C0281176lld:lifeskim
pubmed-article:2297714lifeskim:mentionsumls-concept:C0243019lld:lifeskim
pubmed-article:2297714pubmed:issue3 Suppllld:pubmed
pubmed-article:2297714pubmed:dateCreated1990-3-13lld:pubmed
pubmed-article:2297714pubmed:abstractTextA trial has been initiated testing the effects of high dose radiolabeled monoclonal antibody administered in conjunction with marrow transplantation for treatment of lymphoma. This study is based on observations in mice demonstrating that radiolabeled antibody against a normal lymphocyte-associate antigen can induce regression of lymphoma masses. These preclinical studies also showed that large amounts of antibody are needed to achieve adequate biodistribution in vivo and that potentially curative doses of radionuclide induce substantial hematopoietic toxicity. Consequently, in patients with recurrent lymphoma, we are first evaluating the influence of dose on the biodistribution of a pan B-cell antibody, MB-1 (anti-CD37). In four patients, the biodistribution studies indicated that at the highest amount of antibody tested 131I-labeled antibody MB-1 (10 mg/kg) could deliver more radiation to tumor than to normal organs. These patients were treated with antibody MB-1 labeled with 250 to 482 mCi 131I estimated to deliver 380 to 1570 cGy to normal organs and 850 to 4260 cGy to tumor. Myelosuppression occurred in all patients and required infusion of cryopreserved marrow in one patient. Complete tumor regressions were observed in each patient. In three other patients with splenomegaly and/or large tumor burden, biodistribution studies indicated that 131I-labeled antibody could not deliver more radiation to tumor than to normal organs and these patients were not treated. Thus, tumor burden and spleen size may determine the feasibility of treatment with radiolabeled antibody. Treatment with this antibody labeled with high doses of 131I was well tolerated and may prove therapeutically useful. These studies are being continued to determine the maximal doses of radiation that can be tolerated by nonhematopoietic tissues after infusion of 131I-labeled antibody.lld:pubmed
pubmed-article:2297714pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2297714pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2297714pubmed:languageenglld:pubmed
pubmed-article:2297714pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2297714pubmed:citationSubsetIMlld:pubmed
pubmed-article:2297714pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2297714pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2297714pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2297714pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2297714pubmed:statusMEDLINElld:pubmed
pubmed-article:2297714pubmed:monthFeblld:pubmed
pubmed-article:2297714pubmed:issn0008-5472lld:pubmed
pubmed-article:2297714pubmed:authorpubmed-author:MartinP JPJlld:pubmed
pubmed-article:2297714pubmed:authorpubmed-author:FisherDDlld:pubmed
pubmed-article:2297714pubmed:authorpubmed-author:BernsteinI...lld:pubmed
pubmed-article:2297714pubmed:authorpubmed-author:KrohnK AKAlld:pubmed
pubmed-article:2297714pubmed:authorpubmed-author:PressO WOWlld:pubmed
pubmed-article:2297714pubmed:authorpubmed-author:AppelbaumF...lld:pubmed
pubmed-article:2297714pubmed:authorpubmed-author:NelpW BWBlld:pubmed
pubmed-article:2297714pubmed:authorpubmed-author:PortesCClld:pubmed
pubmed-article:2297714pubmed:authorpubmed-author:EastJ DJDlld:pubmed
pubmed-article:2297714pubmed:authorpubmed-author:BadgerC CCClld:pubmed
pubmed-article:2297714pubmed:issnTypePrintlld:pubmed
pubmed-article:2297714pubmed:day1lld:pubmed
pubmed-article:2297714pubmed:volume50lld:pubmed
pubmed-article:2297714pubmed:ownerNLMlld:pubmed
pubmed-article:2297714pubmed:authorsCompleteNlld:pubmed
pubmed-article:2297714pubmed:pagination1017s-1021slld:pubmed
pubmed-article:2297714pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:2297714pubmed:meshHeadingpubmed-meshheading:2297714-...lld:pubmed
pubmed-article:2297714pubmed:meshHeadingpubmed-meshheading:2297714-...lld:pubmed
pubmed-article:2297714pubmed:meshHeadingpubmed-meshheading:2297714-...lld:pubmed
pubmed-article:2297714pubmed:meshHeadingpubmed-meshheading:2297714-...lld:pubmed
pubmed-article:2297714pubmed:meshHeadingpubmed-meshheading:2297714-...lld:pubmed
pubmed-article:2297714pubmed:meshHeadingpubmed-meshheading:2297714-...lld:pubmed
pubmed-article:2297714pubmed:meshHeadingpubmed-meshheading:2297714-...lld:pubmed
pubmed-article:2297714pubmed:meshHeadingpubmed-meshheading:2297714-...lld:pubmed
pubmed-article:2297714pubmed:meshHeadingpubmed-meshheading:2297714-...lld:pubmed
pubmed-article:2297714pubmed:meshHeadingpubmed-meshheading:2297714-...lld:pubmed
pubmed-article:2297714pubmed:meshHeadingpubmed-meshheading:2297714-...lld:pubmed
pubmed-article:2297714pubmed:year1990lld:pubmed
pubmed-article:2297714pubmed:articleTitleHigh dose radiolabeled antibody therapy of lymphoma.lld:pubmed
pubmed-article:2297714pubmed:affiliationDivision of Pediatric Oncology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98104.lld:pubmed
pubmed-article:2297714pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2297714pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed